Asia-Pacific Melanoma Diagnostics and therapeutic market - segmented by type of cancer and geography (2015-2020)
The Asia-Pacific melanoma diagnostics and therapeutics market was valued at USD 532 million in 2015 and is expected to reach USD 1,172 million by 2020.
Melanoma is one of the serious types of skin cancer that develops from pigment-containing cells called melanocytes. The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities. In addition, government initiatives and technical advancements boost the market growth.
The market for melanoma can be segmented based on:
Superficial spreading melanoma
Lentigno maligna melanoma
Acral lentiginous melanoma
Cutaneous malignant melanoma
Melanoma of vulva
Vaginal melanoma or melanoma of black passage
Sentinel lymph node biopsy
Treatment for early stage melanoma
Surgery (Excision and Mohs surgery)
Treatment for advanced stage melanoma
The Asia-Pacific countries, namely Japan, China and India, are expected to be the fastest-growing melanoma diagnostics and therapeutics markets.
Abbott Diagnostics, Agilent Technologies, Roche, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Qiagen N.V. Company and Teva Pharmaceuticals to name a few, are the key players of this market.
Increase in melanoma incident cases
Approval and uptake of premium-priced products
Label extension of current therapies into the new settings
Lack of awareness in some developing regions
High cost associated with the therapy
PDF E-mail From Publisher
Multi User License (2-5 Users) Fulfilled by Publisher